drugset / Trial / NCT06623136
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2025-04-30
- Primary completion
- 2027-02-28
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES102 | Unknown | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |